RT Journal Article
SR Electronic
T1 Circulating cell-free DNA in serum as a biomarker of colorectal cancer
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 775
OP 778
DO 10.1136/jclinpath-2013-201521
VO 66
IS 9
A1 da Silva Filho, Benisio Ferreira
A1 Gurgel, Ana Pavla Almeida Diniz
A1 Neto, Manoel Álvaro de Freitas Lins
A1 de Azevedo, Dalmo Almeida
A1 de Freitas, Antonio Carlos
A1 Silva Neto, Jacinto da Costa
A1 Silva, Luiz Antonio Ferreira
YR 2013
UL http://jcp.bmj.com/content/66/9/775.abstract
AB Aims The aim of this study was to report circulating cell-free DNA using ALU247 and ALU247/ALU115 biomarkers in serum of operated and non-operated patients with colorectal cancer (CRC). Methods To undertake this, 90 blood samples were collected, including 30 samples from healthy volunteers; 27 samples from CRC non-operated patients and 33 samples from CRC-operated patients. Circulating cell-free DNA was verified through quantitative real-time PCR (qPCR) using ALU115 and ALU247 primers. Results With regard to the ALU115-qPCR biomarker, the increased levels of circulating cell-free DNA in serum of non-operated patients were significant when compared with control (p<0.05). Moreover, levels of ALU247-qPCR biomarker were statistically significant between non-operated versus operated and non-operated versus control groups (p=0.000). With regard to the ALU247/115-qPCR biomarker, significant differences were observed between control versus non-operated patients (p=0.019), operated versus non-operated patients (p=0.005) and control versus operated patients (p=0.043). Conclusions Thus, the ALU247 and ALU247/ALU115-qPCR biomarkers may be important in detecting and monitoring CRC patients in both early and late stages.